BioCryst elects George Abercrombie to board
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals, a developer of novel small molecule drugs that block key enzymes involved in infectious diseases, inflammatory diseases and cancer, has elected George Abercrombie to its board of directors, while Dr Stephen Biggar has stepped down from the board. Mr Abercrombie served as CEO and President of the US arm of Roche from 2001-2009, and recently joined Tranzyme's board (scripintelligence.com, 22 September 2011). He is also chairman of the board at Brickell Biotech.